(Q35917392)

11 August 2017

1 reference

title

Progress in the treatment of a neglected infectious disease: visceral leishmaniasis (English)

1 reference

11 August 2017

main subject

visceral leishmaniasis

1 reference

Henry W Murray

1

1 reference

11 August 2017

language of work or name

1 reference

1 April 2004

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

2

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

279-292

1 reference

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Clinical and experimental advances in treatment of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Kala-azar--progress against a neglected disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Current treatment approaches to leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Visceral leishmaniasis treatment, Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Trial of oral miltefosine for visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Advances in the treatment of leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Short-course, cost-effective treatment with amphotericin B-fat emulsion cures visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Mediterranean visceral leishmaniasis in HIV-negative adults: a retrospective analysis of 64 consecutive cases (1995-2001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Amphotericin B: time for a new "gold standard".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Visceral leishmaniasis (kala-azar) in solid organ transplantation: report of five cases and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Drugs against leishmaniasis: a synergy of technology and partnerships

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

CD40 Signaling Is Impaired in L. major–infected Macrophages and Is Rescued by a p38MAPK Activator Establishing a Host-protective Memory T Cell Response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Determinants of response to interleukin-10 receptor blockade immunotherapy in experimental visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

Interleukin 10 production correlates with pathology in human Leishmania donovani infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.2.279

21 January 2018

Identifiers

DOI

10.1586/14787210.2.2.279

1 reference

11 August 2017

1 reference